Answers are grounded in this paper and cite their sources.
BACKGROUND: Despite modern multimodal therapy for rectal cancer, up to 10% develop local recurrence. Current risk factors do not consider tumor biology, are confined to clinical staging criteria, but form the basis for neoadjuvant therapy decisions. OBJECTIVE: To interrogate biological pathways and traits across 1. primary rectal cancer cured by surgery; 2. primary rectal cancer that recurred following surgery; and 3. locally recurrent rectal cancer. DESIGN: Full tumor sections from a resectional tumor cohort were macrodissected before RNA extraction and bulk Illumina Nova-seq sequencing. Pairwise gene set enrichment analyses, microenvironment cell population deconvolution (MCPCounter) and colorectal cancer Consensus-Molecular-Subtype subtyping were performed. SETTINGS: Two UK centers. PATIENTS: Patients undergoing resectional surgery for primary and locally recurrent rectal cancer with available archival tissue MAIN OUTCOME MEASURES: Biological signatures derived from bulk transcriptomic analysis of tumors. RESULTS: One hundred two tumors were eligible for analysis (28 cured primary rectal cancers, 38 primary rectal cancer that recurred and 36 locally recurrent rectal cancer). Primary rectal cancer that recurred had the highest proportion of neoadjuvant treatment, involved surgical margins, low height and poor differentiation (all p < 0.05). The Top 3 enriched pathways in primary rectal cancer that recurred vs. cured primary rectal cancers were “myogenesis”, “epithelial-mesenchymal transition” and “ KRAS signaling dn” pathways. The Top 3 enriched pathways in locally recurrent rectal cancer vs. primary rectal cancer that recurred & cured primary rectal cancers were “epithelial-mesenchymal transition”, “myogenesis” and hypoxia. The Top 3 down-regulated pathways in both Primary rectal cancer that recurred vs cured primary rectal cancers and locally recurrent rectal cancer vs primary rectal cancer that recurred & cured primary rectal cancers were consistent: “ MYC targets V1”, “E2F targets” and “G2M checkpoint”. In MCPCounter analysis, locally recurrent rectal cancer and primary rectal cancer that recurred relate to lower B-cell and T-cell as well as higher fibroblast, endothelial, neutrophil and monocyte populations (all p < 0.05). Locally recurrent rectal cancer and primary rectal cancer that recurred were most commonly Consensus-Molecular-Subtype-4 tumors, (54.2 and 45.8%, respectively) while cured primary rectal cancers was most commonly Consensus-Molecular-Subtype-2 (54.2%). LIMITATIONS: Modest sized cohort. Risk of confounding bias between groups. CONCLUSIONS: Locally recurrent rectal cancer is associated with stereotypical high-risk biological pathways, dysregulated adaptive immune responses and fibroblast enrichment. These features are present in primary tumors, suggesting potential to develop future early locally recurrent rectal cancer biomarkers.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: